期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 127, 期 -, 页码 106-118出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2018.01.015
关键词
Drug delivery; Transdermal; Microneedle; Protein delivery; Vaccine
资金
- American Diabetes Association (ADA) [1-15-ACE-21]
- JDRF [2-SRA-2016-269-A-N]
- National Science Foundation [1708620]
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F30DK113728] Funding Source: NIH RePORTER
The intrinsic properties of therapeutic proteins generally present a major impediment for transdermal delivery, including their relatively large molecule size and susceptibility to degradation. One solution is to utilize microneedles (MNs), which are capable of painlessly traversing the stratum corneum and directly translocating protein drugs into the systematic circulation. MNs can be designed to incorporate appropriate structural materials as well as therapeutics or formulations with tailored physicochemical properties. This platform technique has been applied to deliver drugs both locally and systemically in applications ranging from vaccination to diabetes and cancer therapy. This review surveys the current design and use of polymeric MNs for transdermal protein delivery. The clinical potential and future translation of MNs are also discussed. (C) 2018 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据